Literature DB >> 16618334

Sleep disruption, daytime somnolence and 'sleep attacks' in Parkinson's disease: a clinical survey in PD patients and age-matched healthy volunteers.

J J Ferreira1, K Desboeuf, M Galitzky, C Thalamas, C Brefel-Courbon, N Fabre, J-M Senard, J-L Montastruc, C Sampaio, O Rascol.   

Abstract

Recent case reports of 'sleep attacks' (SA) in patients with Parkinson's disease (PD) generated concerns about drug-induced daytime somnolence in this population. However, there are nearly no comparative data on sleep and vigilance problems between PD patients and normal controls. We performed a cross-sectional survey in PD patients and age-matched controls using a structured questionnaire on PD history, treatments, co-morbidity, activities of daily living, habits, exercise, sleep pattern, driving, pre-existing nocturnal problems, daytime somnolence, episodes of SA and the circumstances in which such episodes occurred. Daytime somnolence was also measured with the Epworth Sleepiness Scale (ESS) and sleep quality with the Pittsburgh Sleep Quality Index (PSQI). 176 PD patients and 174 controls were included. The same proportion of PD patients (27%) and controls (32%) reported episodes of SA, but these were more frequent in PD patients and occurred more frequently during situations requiring attention (10.8% vs. 1.7%, p<10(-3)). More PD patients had abnormal daytime somnolence (ESS) and poor sleeping quality (PSQI). The most consistent factor associated with SA was the duration of levodopa therapy and the predictive value of an abnormal ESS score was rather poor (40.7%). Abnormal daytime somnolence and poor sleep quality at night are more frequent in PD patients than in normals. However, SA are reported in both groups, although less frequently in the normals during activities that requires attention.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16618334     DOI: 10.1111/j.1468-1331.2006.01262.x

Source DB:  PubMed          Journal:  Eur J Neurol        ISSN: 1351-5101            Impact factor:   6.089


  19 in total

1.  Factors to Consider in the Selection of Dopamine Agonists for Older Persons with Parkinson's Disease.

Authors:  Mark Dominic Latt; Simon Lewis; Olfat Zekry; Victor S C Fung
Journal:  Drugs Aging       Date:  2019-03       Impact factor: 3.923

Review 2.  Circadian dysfunction may be a key component of the non-motor symptoms of Parkinson's disease: insights from a transgenic mouse model.

Authors:  L David Willison; Takashi Kudo; Dawn H Loh; Dika Kuljis; Christopher S Colwell
Journal:  Exp Neurol       Date:  2013-01-24       Impact factor: 5.330

Review 3.  Excessive daytime sleepiness and unintended sleep episodes associated with Parkinson's disease.

Authors:  Fatai Salawu; Abdulfatai Olokoba
Journal:  Oman Med J       Date:  2015-01

4.  Do Parkinson's disease patients disclose their adverse events spontaneously?

Authors:  Santiago Perez-Lloret; María Verónica Rey; Nelly Fabre; Fabienne Ory; Umberto Spampinato; Jean-Louis Montastruc; Olivier Rascol
Journal:  Eur J Clin Pharmacol       Date:  2011-12-29       Impact factor: 2.953

5.  Impact of nocturnal calf cramping on quality of sleep and health-related quality of life.

Authors:  Fiona Hawke; Vivienne Chuter; Joshua Burns
Journal:  Qual Life Res       Date:  2012-09-26       Impact factor: 4.147

Review 6.  A systematic review of the literature on disorders of sleep and wakefulness in Parkinson's disease from 2005 to 2015.

Authors:  Lama M Chahine; Amy W Amara; Aleksandar Videnovic
Journal:  Sleep Med Rev       Date:  2016-08-31       Impact factor: 11.609

Review 7.  Dopamine receptor agonists for the treatment of early or advanced Parkinson's disease.

Authors:  Santiago Perez-Lloret; Olivier Rascol
Journal:  CNS Drugs       Date:  2010-11       Impact factor: 5.749

8.  Sleep dysfunction and its management in Parkinson's disease.

Authors:  Scott J Kutscher; Siavash Farshidpanah; Daniel O Claassen
Journal:  Curr Treat Options Neurol       Date:  2014-08       Impact factor: 3.598

Review 9.  'Sleep attacks' or 'unintended sleep episodes' occur with dopamine agonists: is this a class effect?

Authors:  K Ray Chaudhuri; Suvankar Pal; Christine Brefel-Courbon
Journal:  Drug Saf       Date:  2002       Impact factor: 5.606

10.  Sleep disturbance in mental health problems and neurodegenerative disease.

Authors:  Kirstie N Anderson; Andrew J Bradley
Journal:  Nat Sci Sleep       Date:  2013-05-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.